217 related articles for article (PubMed ID: 25936523)
21. mTORC1 signalling and eIF4E/4E-BP1 translation initiation factor stoichiometry influence recombinant protein productivity from GS-CHOK1 cells.
Jossé L; Xie J; Proud CG; Smales CM
Biochem J; 2016 Dec; 473(24):4651-4664. PubMed ID: 27760840
[TBL] [Abstract][Full Text] [Related]
22. Protein kinase C and P2Y12 take center stage in thrombin-mediated activation of mammalian target of rapamycin complex 1 in human platelets.
Moore SF; Hunter RW; Hers I
J Thromb Haemost; 2014 May; 12(5):748-60. PubMed ID: 24612393
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis C virus NS5A binds to the mRNA cap-binding eukaryotic translation initiation 4F (eIF4F) complex and up-regulates host translation initiation machinery through eIF4E-binding protein 1 inactivation.
George A; Panda S; Kudmulwar D; Chhatbar SP; Nayak SC; Krishnan HH
J Biol Chem; 2012 Feb; 287(7):5042-58. PubMed ID: 22184107
[TBL] [Abstract][Full Text] [Related]
24. mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells.
Liu J; Stevens PD; Gao T
J Biol Chem; 2011 Feb; 286(8):6510-20. PubMed ID: 21177869
[TBL] [Abstract][Full Text] [Related]
25. Regulated in development and DNA damage 1 is necessary for hyperglycemia-induced vascular endothelial growth factor expression in the retina of diabetic rodents.
Dennis MD; Kimball SR; Fort PE; Jefferson LS
J Biol Chem; 2015 Feb; 290(6):3865-74. PubMed ID: 25548280
[TBL] [Abstract][Full Text] [Related]
26. Inactivation of the mTORC1-eukaryotic translation initiation factor 4E pathway alters stress granule formation.
Fournier MJ; Coudert L; Mellaoui S; Adjibade P; Gareau C; Côté MF; Sonenberg N; Gaudreault RC; Mazroui R
Mol Cell Biol; 2013 Jun; 33(11):2285-301. PubMed ID: 23547259
[TBL] [Abstract][Full Text] [Related]
27. Re-evaluating the roles of proposed modulators of mammalian target of rapamycin complex 1 (mTORC1) signaling.
Wang X; Fonseca BD; Tang H; Liu R; Elia A; Clemens MJ; Bommer UA; Proud CG
J Biol Chem; 2008 Nov; 283(45):30482-92. PubMed ID: 18676370
[TBL] [Abstract][Full Text] [Related]
28. Phosphatidylinositol-3 kinase-dependent translational regulation of Id1 involves the PPM1G phosphatase.
Xu K; Wang L; Feng W; Feng Y; Shu HK
Oncogene; 2016 Nov; 35(44):5807-5816. PubMed ID: 27065332
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of mTORC1 by SU6656, the selective Src kinase inhibitor, is not accompanied by activation of Akt/PKB signalling in melanoma cells.
Ondrušová L; Réda J; Záková P; Tuháčková Z
Folia Biol (Praha); 2013; 59(4):162-7. PubMed ID: 24093774
[TBL] [Abstract][Full Text] [Related]
30. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
[TBL] [Abstract][Full Text] [Related]
31. Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation.
Cope CL; Gilley R; Balmanno K; Sale MJ; Howarth KD; Hampson M; Smith PD; Guichard SM; Cook SJ
J Cell Sci; 2014 Feb; 127(Pt 4):788-800. PubMed ID: 24363449
[TBL] [Abstract][Full Text] [Related]
32. Phosphorylation of eIF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells.
Bianchini A; Loiarro M; Bielli P; Busà R; Paronetto MP; Loreni F; Geremia R; Sette C
Carcinogenesis; 2008 Dec; 29(12):2279-88. PubMed ID: 18809972
[TBL] [Abstract][Full Text] [Related]
33. 4E-BPs Control Fat Storage by Regulating the Expression of Egr1 and ATGL.
Singh M; Shin YK; Yang X; Zehr B; Chakrabarti P; Kandror KV
J Biol Chem; 2015 Jul; 290(28):17331-8. PubMed ID: 25814662
[TBL] [Abstract][Full Text] [Related]
34. 4E-BP1, a multifactor regulated multifunctional protein.
Qin X; Jiang B; Zhang Y
Cell Cycle; 2016; 15(6):781-6. PubMed ID: 26901143
[TBL] [Abstract][Full Text] [Related]
35. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
[TBL] [Abstract][Full Text] [Related]
36. mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms.
Wilson-Edell KA; Yevtushenko MA; Rothschild DE; Rogers AN; Benz CC
Breast Cancer Res Treat; 2014 Apr; 144(2):287-298. PubMed ID: 24562770
[TBL] [Abstract][Full Text] [Related]
37. mTORC2 is required for proliferation and survival of TSC2-null cells.
Goncharova EA; Goncharov DA; Li H; Pimtong W; Lu S; Khavin I; Krymskaya VP
Mol Cell Biol; 2011 Jun; 31(12):2484-98. PubMed ID: 21482669
[TBL] [Abstract][Full Text] [Related]
38. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
39. Heterozygous inactivation of tsc2 enhances tumorigenesis in p53 mutant zebrafish.
Kim SH; Kowalski ML; Carson RP; Bridges LR; Ess KC
Dis Model Mech; 2013 Jul; 6(4):925-33. PubMed ID: 23580196
[TBL] [Abstract][Full Text] [Related]
40. Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition.
Yoon SO; Shin S; Karreth FA; Buel GR; Jedrychowski MP; Plas DR; Dedhar S; Gygi SP; Roux PP; Dephoure N; Blenis J
Mol Cell; 2017 Aug; 67(3):512-527.e4. PubMed ID: 28757207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]